摘要
目的:分析依帕司他联合丁苯酞软胶囊对痛性糖尿病周围神经病变(PDPN)患者的影响。方法:选取2021年2月—2022年2月通城县人民医院收治的80例PDPN患者作为研究对象,根据掷硬币法将患者分为对照组和研究组,各40例。对照组给予依帕司他,研究组在对照组基础上给予丁苯酞软胶囊,比较两组临床疗效、不良反应、疼痛程度[视觉模拟评分法(VAS)]、正中神经、腓总神经、尺神经的感觉神经传导速度(SNCV)、运动神经传导速度(MNCV)及氧化应激指标[超氧化物歧化酶(SOD),丙二醛(MDA)]水平。结果:研究组临床总有效率高于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05);治疗1个月后,两组VAS评分低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);治疗1个月后,两组正中神经、腓总神经、尺神经的SNCV和MNCV较治疗前提高,且研究组高于对照组,差异有统计学意义(P<0.05);治疗1个月后,两组SOD和MDA水平较治疗前改善,且研究组SOD水平高于对照组,MDA水平低于对照组,差异有统计学意义(P<0.05)。结论:依帕司他与丁苯酞软胶囊联合治疗PNDN,临床疗效好,不良反应发生率较低,能显著降低疼痛程度,提高正中神经、腓总神经、尺神经SNCV和MNCV,改善SOD和MDA水平。
Objective:To analyze the effect of Epalrestat combined with Butylphthalide Soft Capsules on patients with painful diabetic peripheral neuropathy(PDPN).Method:A total of 80 patients with PDPN who admitted to Tongcheng County People's Hospital from February 2021 to February 2022 were selected as the study objects,and the patients were divided into the study group and the control group according to the coin toss method,with 40 patients in each group.The control group was given Epalrestat,and the study group was given Butylphthalide Soft Capsules on the basis of the control group.The clinical efficacy,adverse reactions,pain degree[visual analogue scale(VAS)],sensory nerve conduction velocity(SNCV),motor nerve conduction velocity(MNCV)of median nerve,common peroneal nerve and ulnar nerve and oxidative stress index[superoxide dismutase(SOD),malondialdehyde(MDA)]levels were compared between two groups.Result:The total effective rate of the study group was significantly higher than that of the control group,the difference was statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between two groups(P>0.05).After 1 month of treatment,the VAS scores of two groups were lower than those before treatment,and that in the study group was lower than that in the control group,the differences were statistically significant(P<0.05).After 1 month of treatment,the SNCV and MNCV of median nerve,common peroneal nerve and ulnar nerve in two groups increased compared with those before treatment,and which in the study group were higher than those in the control group,the differences were statistically significant(P<0.05).After 1 month of treatment,the levels of SOD and MDA in two groups were improved compared with those before treatment,and the level of SOD in the study group was higher than that in the control group,and the level of MDA was lower than that in the control group,the differences were statistically significant(P<0.05).Conclusion:Epalrestat combined with Butylphthalide Soft Capsules in the treatment of PDPN has a better clinical effect,which can significantly reduce the degree of pain after treatment it can effectively improve SNCV and MNCV of median nerve,common peroneal nerve and ulnar nerve,and reduce SOD and MDA levels.
作者
郑玲
胡华龙
ZHENG Ling;HU Hualong(Tongcheng County People's Hospital,Tongcheng 437400,China;不详)
出处
《中外医学研究》
2024年第4期115-118,共4页
CHINESE AND FOREIGN MEDICAL RESEARCH
关键词
依帕司他
丁苯酞软胶囊
痛性糖尿病周围神经病变
感觉神经传导速度
运动神经传导速度
Epalrestat
Butylphthalide Soft Capsules
Painful diabetic peripheral neuropathy
Sensory nerve conduction velocity
Motor nerve conduction velocity
